MCID: BSL007
MIFTS: 65

Basal Cell Carcinoma malady

Categories: Cancer diseases, Skin diseases, Genetic diseases, Respiratory diseases, Rare diseases

Aliases & Classifications for Basal Cell Carcinoma

Aliases & Descriptions for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 12 14 69
Basal Cell Neoplasm 12 29 69
Basal Cell Cancer 12 52 69
Malignant Basal Cell Tumor 12 69
Experimental Organism Basal Cell Carcinoma 69
Nodulo-Ulcerative Basal Cell Carcinoma 69
Malignant Basal Cell Neoplasm 12
Basal Cell Carcinoma of Skin 12
Basal Cell Carcinoma Nos 12
Basal Cell Neoplasm Nos 12
Epithelioma Basal Cell 12
Carcinoma, Basal Cell 42
Neoplasms, Basal Cell 42
Carcinoma Basal Cell 52
Basal Cell Tumor 12
Rodent Ulcer 12

Classifications:



Summaries for Basal Cell Carcinoma

Disease Ontology : 12 A skin carcinoma affecting basal cells.

MalaCards based summary : Basal Cell Carcinoma, also known as basal cell neoplasm, is related to basal cell carcinoma 1 and superficial basal cell carcinoma. An important gene associated with Basal Cell Carcinoma is PTCH1 (Patched 1), and among its related pathways/superpathways are Basal cell carcinoma and Signaling by GPCR. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and t cells, and related phenotypes are cellular and digestive/alimentary

Wikipedia : 71 Basal cell carcinoma (BCC) is the most common skin cancer, and one of the most common cancers in the... more...

Related Diseases for Basal Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 6
Basal Cell Carcinoma 5 Basal Cell Carcinoma 4
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
id Related Disease Score Top Affiliating Genes
1 basal cell carcinoma 1 34.1 PTCH1 PTCH2 SMO
2 superficial basal cell carcinoma 33.9 KRT17 KRT7
3 infiltrative basal cell carcinoma 33.5 KRT15 KRT17 KRT19 KRT20
4 sarcomatoid basal cell carcinoma 33.4 KRT15 KRT17 KRT20 KRT7 TP53
5 anal margin basal cell carcinoma 33.4 KRT17 KRT20 PTCH1 SUFU
6 basal cell carcinoma 7 33.0 CTNNB1 GLI1 KRT19 SHH SMO TP53
7 basal cell nevus syndrome 32.9 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
8 nodular basal cell carcinoma 12.2
9 infundibulocystic basal cell carcinoma 12.2
10 morpheaform basal cell carcinoma 12.2
11 pigmented basal cell carcinoma 12.1
12 adenoid basal cell carcinoma 12.1
13 clear cell basal cell carcinoma 12.1
14 cystic basal cell carcinoma 12.1
15 metatypical basal cell carcinoma 12.1
16 micronodular basal cell carcinoma 12.1
17 fibroepithelial basal cell carcinoma 12.1
18 basal cell carcinoma, multiple 12.0
19 vulva basal cell carcinoma 12.0
20 external ear basal cell carcinoma 12.0
21 follicular basal cell carcinoma 12.0
22 scrotum basal cell carcinoma 12.0
23 signet ring basal cell carcinoma 12.0
24 basal cell carcinoma 4 11.9
25 basal cell carcinoma 2 11.9
26 penis basal cell carcinoma 11.9
27 basal cell carcinoma 3 11.9
28 sebaceous basal cell carcinoma 11.9
29 basal cell carcinoma 6 11.9
30 basal cell carcinoma 5 11.9
31 bazex syndrome 11.8
32 rombo syndrome 11.8
33 brooke-spiegler syndrome 11.2
34 multiple familial trichoepithelioma 11.2
35 adamantinoid basal cell epithelioma 11.0
36 trichoepithelioma, multiple familial, 1 11.0
37 eosinophilic granuloma 10.9
38 prostate cancer, hereditary, 13 10.8
39 clear cell acanthoma 10.8
40 prostate cancer 1 10.8
41 prostate cancer 10.8
42 cerebrooculofacioskeletal syndrome 3 10.8
43 prostate cancer, hereditary, 12 10.8
44 prostate cancer, hereditary, 2 10.8
45 xeroderma pigmentosum, variant type 10.8
46 prostate cancer, hereditary, 11 10.8
47 inflammatory linear verrucous epidermal nevus 10.8
48 squamous cell carcinoma 10.5
49 keratosis 10.4
50 melanoma 10.4

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to Basal Cell Carcinoma

Symptoms & Phenotypes for Basal Cell Carcinoma

MGI Mouse Phenotypes related to Basal Cell Carcinoma:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 KRT19 KRT7 MC1R PTCH1 SHH SMO
2 digestive/alimentary MP:0005381 10.38 PTCH2 SHH SMO SUFU TP53 CTNNB1
3 craniofacial MP:0005382 10.35 CTNNB1 GLI1 GLI2 GLI3 HHIP KRT17
4 growth/size/body region MP:0005378 10.35 CTNNB1 GLI1 GLI2 GLI3 HHIP KRT17
5 embryo MP:0005380 10.3 PTCH1 SHH SMO SUFU TP53 CTNNB1
6 cardiovascular system MP:0005385 10.29 PTCH2 SHH SMO SUFU TP53 CTNNB1
7 integument MP:0010771 10.25 CTNNB1 GLI2 GLI3 KRT17 KRT19 MC1R
8 nervous system MP:0003631 10.23 CTNNB1 GLI1 GLI2 GLI3 HHIP KRT19
9 endocrine/exocrine gland MP:0005379 10.2 CTNNB1 GLI1 GLI2 GLI3 HHIP KRT19
10 limbs/digits/tail MP:0005371 10.19 CTNNB1 GLI1 GLI2 GLI3 MC1R PTCH1
11 neoplasm MP:0002006 10.18 CTNNB1 GLI1 KRT19 MC1R MMP11 PTCH1
12 no phenotypic analysis MP:0003012 10.17 GLI2 GLI3 KRT17 KRT19 MC1R PTCH1
13 normal MP:0002873 10.14 CTNNB1 GLI1 GLI2 GLI3 KRT19 PTCH1
14 hearing/vestibular/ear MP:0005377 10.07 CTNNB1 GLI2 GLI3 MC1R SHH SMO
15 pigmentation MP:0001186 9.91 KRT17 MC1R PTCH1 SUFU TP53 CTNNB1
16 reproductive system MP:0005389 9.91 CTNNB1 GLI1 GLI2 GLI3 KRT19 PTCH1
17 renal/urinary system MP:0005367 9.87 TP53 CTNNB1 GLI1 GLI3 KRT7 PTCH1
18 respiratory system MP:0005388 9.85 CTNNB1 GLI1 GLI2 GLI3 HHIP PTCH1
19 skeleton MP:0005390 9.65 CTNNB1 GLI2 GLI3 KRT19 PTCH1 SHH
20 vision/eye MP:0005391 9.28 TP53 CTNNB1 GLI2 GLI3 HHIP PTCH1

Drugs & Therapeutics for Basal Cell Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erivedge 17 46 VISMODEGIB Genentech Approved January 2012
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
3
Odomzo 17 46 SONIDEGIB PHOSPHATE Novartis Jul-15

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 329)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
2
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 106-60-5 137
3
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
5
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
6
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
9
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
10
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
11
Nitric Oxide Approved Phase 4 10102-43-9 145068
12
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
13 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
14 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
15 interferons Phase 4,Phase 3,Phase 2,Phase 1
16 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1
18 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antiviral Agents Phase 4,Phase 2,Phase 1
21 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
24 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
25 Antirheumatic Agents Phase 4,Phase 2,Phase 3
26 Interferon-alpha Phase 4
27 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
28 Tin Fluorides Phase 4
29 triamcinolone acetonide Phase 4,Phase 2
30 Triamcinolone diacetate Phase 4,Phase 2
31 Triamcinolone hexacetonide Phase 4,Phase 2
32 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Calcineurin Inhibitors Phase 4,Phase 2
34
Proton pump inhibitors Phase 4
35 Bone Density Conservation Agents Phase 4,Phase 2,Phase 1
36 Calcifediol Phase 4 19356-17-3
37 Ergocalciferols Phase 4,Phase 2
38 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
40 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
41 vitamin d Phase 4,Phase 2
42 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
43 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
44 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
45 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Asthmatic Agents Phase 4
49 Bronchodilator Agents Phase 4
50 Respiratory System Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 342)
id Name Status NCT ID Phase
1 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4
2 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4
3 A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Approved for marketing NCT01160250 Phase 4
4 Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage Completed NCT00314756 Phase 4
5 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4
6 Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) Completed NCT00581425 Phase 4
7 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4
8 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4
9 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4
10 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4
11 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4
12 N-Acetylcysteine and Arginine Administration in Diabetic Patients Terminated NCT00569465 Phase 4
13 Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control Unknown status NCT00663650 Phase 3
14 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
15 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Completed NCT00189306 Phase 3
16 Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery Completed NCT01212562 Phase 3
17 A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3
18 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
19 Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
20 A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence Completed NCT00129519 Phase 3
21 Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Completed NCT01212549 Phase 3
22 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3
23 Metvix PDT in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
24 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3
25 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3
26 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Completed NCT00472043 Phase 3
27 Fractional CO2 Laser Assisted Photodynamic Therapy Completed NCT01260987 Phase 2, Phase 3
28 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3
29 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3
30 Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals. Completed NCT00272428 Phase 3
31 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
32 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
33 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
34 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
35 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
36 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
37 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed NCT02152371 Phase 3
38 Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma Recruiting NCT02242929 Phase 3
39 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3
40 Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy Recruiting NCT02445391 Phase 3
41 A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer Recruiting NCT03168880 Phase 3
42 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3
43 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy Active, not recruiting NCT02144077 Phase 3
44 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
45 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Active, not recruiting NCT01362140 Phase 3
46 Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With T Active, not recruiting NCT01640405 Phase 3
47 Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. Terminated NCT00049959 Phase 3
48 Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients Terminated NCT01532453 Phase 3
49 Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Withdrawn NCT03070691 Phase 2, Phase 3
50 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, basal cell

Genetic Tests for Basal Cell Carcinoma

Genetic tests related to Basal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Basal Cell Carcinoma 29

Anatomical Context for Basal Cell Carcinoma

MalaCards organs/tissues related to Basal Cell Carcinoma:

39
Skin, Prostate, T Cells, Testes, Thyroid, Liver, Breast

Publications for Basal Cell Carcinoma

Articles related to Basal Cell Carcinoma:

(show top 50) (show all 1740)
id Title Authors Year
1
Differential BMI1, TWIST1, SNAI2 mRNA expression pattern correlation with malignancy type in a spectrum of common cutaneous malignancies: basal cell carcinoma, squamous cell carcinoma, and melanoma. ( 27718152 )
2017
2
FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. ( 28073840 )
2017
3
Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma. ( 28177523 )
2017
4
Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. ( 28089000 )
2017
5
Use of a cotton-tipped applicator for superior clinical diagnosis and biopsy of suspected basal cell carcinoma of the nasal ala. ( 27986150 )
2017
6
The concerted action of type 2 and type 3 deiodinases regulates the cell cycle and survival of basal cell carcinoma cells. ( 28088877 )
2017
7
Reflectance confocal microscopy as a noninvasive diagnostic tool for naevoid basal cell carcinoma syndrome management. ( 28044368 )
2017
8
A rare dermoscopic pattern of nodular basal cell carcinoma with amyloid deposition. ( 28087032 )
2017
9
Dynamic Thiol/Disulphide Homeostasis in patients with Basal Cell Carcinoma. ( 28067074 )
2017
10
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
11
Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. ( 28088999 )
2017
12
Nevoid Basal Cell Carcinoma Syndrome - Clinical and Radiological Findings of Three Cases. ( 27630800 )
2016
13
Ameloblastoma vs basal cell carcinoma: an immunohistochemical comparison. ( 27806852 )
2016
14
Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma. ( 27406386 )
2016
15
Treatment of Pigmented Basal Cell Carcinoma with 3a88mm Surgical Margin in Asians. ( 27652267 )
2016
16
Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment. ( 28002101 )
2016
17
Nodulocystic Basal Cell Carcinoma Arising Directly from a Seborrheic Keratosis: A Rare Case Report. ( 27512194 )
2016
18
Preoperative prediction of histopathologic outcome in basal cell carcinoma - flat surface and multiple small erosions predict superficial basal cell carcinoma in lighter skin types. ( 26921200 )
2016
19
Pigmented basal cell carcinoma mimicking a superficial spreading melanoma. ( 28076343 )
2016
20
Marking sutures to orientate specimens of basal cell carcinoma: do they really make a difference? ( 27126978 )
2016
21
Case of nodular melanoma on the upper eyelid dermoscopically mimicking pigmented basal cell carcinoma. ( 27649925 )
2016
22
The Rare Phenomenon of Tumor-to-Tumor Metastasis: Melanoma Metastatic to a Basal Cell Carcinoma. ( 27605090 )
2016
23
A retrospective study on the effectiveness of curettage and electrodesiccation for clinically suspected primary nodular basal cell carcinoma. ( 27229620 )
2016
24
Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry. ( 27902821 )
2016
25
Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%. ( 27574458 )
2016
26
The activity and tissue distribution of thioredoxin reductase in basal cell carcinoma. ( 27601162 )
2016
27
The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. ( 27636236 )
2016
28
Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma - a prospective, consecutive, cohort study of 168 cases. ( 27146027 )
2016
29
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. ( 27714753 )
2016
30
Diagnostic Accuracy in Subtyping Basal Cell Carcinoma by Clinical Diagnosis Compared with Punch Biopsy. ( 27140830 )
2016
31
Soluble interleukin-2 receptor I+ and interleukin-2 serum levels in patients with basal cell carcinoma. ( 27605896 )
2016
32
Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. ( 27359199 )
2016
33
Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. ( 26985197 )
2016
34
Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015. ( 27904293 )
2016
35
PCR Quantification of D. folliculorum in Periocular Basal Cell Carcinoma. ( 27615600 )
2016
36
Incidence of eyelid basal cell carcinoma in England: 2000-2010. ( 27130914 )
2016
37
A Case-Control Study of Involvement of Oxidative DNA Damage and Alteration of Antioxidant Defense System in Patients with Basal Cell Carcinoma: Modulation by Tumor Removal. ( 27057281 )
2016
38
Pigmented Basal Cell Carcinoma: Increased Melanin or Increased Melanocytes? ( 27612950 )
2016
39
Unusual Presentation of Pigmented Basal Cell Carcinoma of Face: Surgical Challenge. ( 27630973 )
2016
40
Altered Expression of PRKX, WNT3 and WNT16 in Human Nodular Basal Cell Carcinoma. ( 27630294 )
2016
41
Adenoid basal cell carcinoma: a rare facet of basal cell carcinoma. ( 27095806 )
2016
42
Differentiation of Basal Cell Carcinoma Subtypes in Multi-Beam Swept Source Optical Coherence Tomography (MSS-OCT). ( 27168263 )
2016
43
Basal Cell Carcinoma of the Dorsal Foot: An Update and Comprehensive Review of the Literature. ( 27631459 )
2016
44
Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma. ( 27218790 )
2016
45
Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study. ( 27152747 )
2016
46
A Case of Orbital Myiasis in Recurrent Eyelid Basal Cell Carcinoma Invasive into the Orbit. ( 27595028 )
2016
47
Topical Photodynamic Therapy for Primary Bowen's Disease and Basal Cell Carcinoma - Optimising Patient Selection. ( 28028807 )
2016
48
Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis? ( 27256516 )
2016
49
Gorlin Syndrome, Vulvar Basal Cell Carcinomas, Vismodegib, and Lichen Sclerosus: From the ISSVD Case Consultation Committee. ( 27105331 )
2016
50
Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma. ( 27519350 )
2016

Variations for Basal Cell Carcinoma

ClinVar genetic disease variations for Basal Cell Carcinoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.1451T> A (p.Leu484Ter) single nucleotide variant Pathogenic rs786203714 GRCh37 Chromosome 16, 23646416: 23646416
2 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh37 Chromosome 7, 128849189: 128849189

Cosmic variations for Basal Cell Carcinoma:

9 (show top 50) (show all 223)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44130 TP53 skin,NS,carcinoma,basal cell carcinoma c.477C>T p.A159A 20
2 COSM43920 TP53 skin,NS,carcinoma,basal cell carcinoma c.680C>T p.S227F 20
3 COSM10705 TP53 skin,NS,carcinoma,basal cell carcinoma c.586C>T p.R196* 20
4 COSM10654 TP53 skin,NS,carcinoma,basal cell carcinoma c.637C>T p.R213* 20
5 COSM45774 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 20
6 COSM11084 TP53 skin,NS,carcinoma,basal cell carcinoma c.517G>A p.V173M 20
7 COSM10662 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>A p.R248Q 20
8 COSM44097 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 20
9 COSM44603 TP53 skin,NS,carcinoma,basal cell carcinoma c.835G>A p.G279R 20
10 COSM45424 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 20
11 COSM44435 TP53 skin,NS,carcinoma,basal cell carcinoma c.96+1G>A p.? 20
12 COSM10659 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 20
13 COSM10728 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 20
14 COSM43837 TP53 skin,NS,carcinoma,basal cell carcinoma c.843C>G p.D281E 20
15 COSM10749 TP53 skin,NS,carcinoma,basal cell carcinoma c.830G>T p.C277F 20
16 COSM45322 TP53 skin,NS,carcinoma,basal cell carcinoma c.757A>G p.T253A 20
17 COSM10995 TP53 skin,NS,carcinoma,basal cell carcinoma c.580C>T p.L194F 20
18 COSM43582 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 20
19 COSM10656 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 20
20 COSM10650 TP53 skin,NS,carcinoma,basal cell carcinoma c.529C>T p.P177S 20
21 COSM11152 TP53 skin,NS,carcinoma,basal cell carcinoma c.700T>C p.Y234H 20
22 COSM10726 TP53 skin,NS,carcinoma,basal cell carcinoma c.856G>A p.E286K 20
23 COSM10794 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 20
24 COSM10939 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 20
25 COSM10648 TP53 skin,NS,carcinoma,basal cell carcinoma c.524G>A p.R175H 20
26 COSM45304 TP53 skin,NS,carcinoma,basal cell carcinoma c.375+1G>A p.? 20
27 COSM44398 TP53 skin,NS,carcinoma,basal cell carcinoma c.682G>A p.D228N 20
28 COSM44606 TP53 skin,NS,carcinoma,basal cell carcinoma c.665C>T p.P222L 20
29 COSM44310 TP53 skin,NS,carcinoma,basal cell carcinoma c.738G>A p.M246I 20
30 COSM11376 TP53 skin,NS,carcinoma,basal cell carcinoma c.737T>G p.M246R 20
31 COSM10867 TP53 skin,NS,carcinoma,basal cell carcinoma c.797G>A p.G266E 20
32 COSM10812 TP53 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.S241F 20
33 COSM10704 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 20
34 COSM43842 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 20
35 COSM6549 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>T p.R248L 20
36 COSM45733 TP53 skin,NS,carcinoma,basal cell carcinoma c.432G>A p.Q144Q 20
37 COSM6932 TP53 skin,NS,carcinoma,basal cell carcinoma c.733G>A p.G245S 20
38 COSM44226 TP53 skin,NS,carcinoma,basal cell carcinoma c.380C>T p.S127F 20
39 COSM10768 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 20
40 COSM10905 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 20
41 COSM43714 TP53 skin,NS,carcinoma,basal cell carcinoma c.836G>A p.G279E 20
42 COSM43583 TP53 skin,NS,carcinoma,basal cell carcinoma c.425C>T p.P142L 20
43 COSM10863 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>T p.P278L 20
44 COSM11449 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 20
45 COSM43700 TP53 skin,NS,carcinoma,basal cell carcinoma c.712T>A p.C238S 20
46 COSM45751 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 20
47 COSM44126 TP53 skin,NS,carcinoma,basal cell carcinoma c.507G>A p.M169I 20
48 COSM45074 TP53 skin,NS,carcinoma,basal cell carcinoma c.829T>G p.C277G 20
49 COSM10988 TP53 skin,NS,carcinoma,basal cell carcinoma c.772G>A p.E258K 20
50 COSM45732 TP53 skin,NS,carcinoma,basal cell carcinoma c.480G>C p.M160I 20

Copy number variations for Basal Cell Carcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 256908 9 98205264 98279247 Mutation PTCH Basal cell carcinoma

Expression for Basal Cell Carcinoma

Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for Basal Cell Carcinoma

Pathways related to Basal Cell Carcinoma according to KEGG:

37
id Name Kegg Source Accession
1 Basal cell carcinoma hsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CTNNB1 GLI1 GLI2 GLI3 HHIP MC1R
2
Show member pathways
12.8 GLI1 GLI2 GLI3 PTCH1 PTCH2 SMO
3
Show member pathways
12.55 GLI1 GLI2 GLI3 HHIP PTCH1 SHH
4
Show member pathways
12.36 KRT15 KRT17 KRT19 KRT20 KRT7
5 12.33 CTNNB1 GLI1 GLI2 GLI3 HHIP PTCH1
6
Show member pathways
12.27 PTCH1 PTCH2 SHH SMO WNT16
7 12.24 CTNNB1 PTCH1 SHH SMO TP53 WNT16
8
Show member pathways
12.15 GLI1 GLI3 HHIP PTCH1
9 12.12 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
10 12.04 CTNNB1 MMP11 TP53 WNT16
11
Show member pathways
11.92 GLI1 GLI2 GLI3 HHIP PTCH1 PTCH2
12
Show member pathways
11.79 CTNNB1 GLI1 GLI2 GLI3 HHIP MC1R
13 11.36 GLI1 GLI2 PTCH1 SHH SMO
14
Show member pathways
11.21 GLI2 HHIP PTCH1 PTCH2 SHH SMO
15 11.15 GLI1 GLI2 SHH
16 10.51 GLI3 SHH
17 10.44 PTCH1 SHH

GO Terms for Basal Cell Carcinoma

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.65 KRT15 KRT17 KRT19 KRT20 KRT7
2 cilium GO:0005929 9.63 GLI1 GLI2 GLI3 PTCH1 SMO SUFU
3 axoneme GO:0005930 9.61 GLI1 GLI2 GLI3
4 cell periphery GO:0071944 9.54 CTNNB1 KRT17 KRT19
5 ciliary membrane GO:0060170 9.5 HHIP PTCH1 SMO
6 ciliary base GO:0097546 9.26 GLI1 GLI2 GLI3 SUFU
7 ciliary tip GO:0097542 9.02 GLI1 GLI2 GLI3 SMO SUFU
8 cytosol GO:0005829 10.22 CTNNB1 GLI1 GLI2 GLI3 GSTM3 KRT15

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
id Name GO ID Score Top Affiliating Genes
1 anterior/posterior pattern specification GO:0009952 9.99 GLI2 GLI3 SHH SMO
2 lung development GO:0030324 9.99 CTNNB1 GLI1 GLI2 GLI3 SHH
3 canonical Wnt signaling pathway GO:0060070 9.94 CTNNB1 GLI1 SHH
4 embryonic digit morphogenesis GO:0042733 9.94 CTNNB1 GLI2 GLI3 SHH
5 forebrain development GO:0030900 9.93 CTNNB1 GLI3 SHH
6 determination of left/right symmetry GO:0007368 9.93 SHH SMO SUFU
7 skin development GO:0043588 9.93 CTNNB1 PTCH2 SHH SUFU
8 response to estrogen GO:0043627 9.92 GLI3 GSTM3 KRT19
9 negative regulation of cell differentiation GO:0045596 9.92 CTNNB1 GLI3 SHH
10 vasculogenesis GO:0001570 9.92 CTNNB1 SHH SMO
11 heart looping GO:0001947 9.92 SHH SMO SUFU
12 branching involved in ureteric bud morphogenesis GO:0001658 9.92 CTNNB1 GLI3 PTCH1 SHH
13 embryonic limb morphogenesis GO:0030326 9.91 GLI3 PTCH1 SHH
14 embryonic organ development GO:0048568 9.91 GLI3 PTCH1 SHH SMO
15 limb development GO:0060173 9.9 CTNNB1 GLI3 SHH
16 mammary gland development GO:0030879 9.89 GLI2 GLI3 PTCH1
17 T cell differentiation in thymus GO:0033077 9.88 CTNNB1 GLI3 SHH
18 branching morphogenesis of an epithelial tube GO:0048754 9.88 GLI2 GLI3 SHH
19 developmental growth GO:0048589 9.88 GLI2 GLI3 SHH SMO
20 positive regulation of smoothened signaling pathway GO:0045880 9.87 GLI1 SHH SMO
21 positive regulation of mesenchymal cell proliferation GO:0002053 9.87 CTNNB1 SHH SMO
22 hair follicle morphogenesis GO:0031069 9.87 CTNNB1 KRT17 SHH SMO
23 hindbrain development GO:0030902 9.86 CTNNB1 GLI2 SHH
24 regulation of smoothened signaling pathway GO:0008589 9.86 GLI1 GLI2 PTCH1
25 cell fate determination GO:0001709 9.85 CTNNB1 PTCH1 PTCH2
26 anatomical structure formation involved in morphogenesis GO:0048646 9.85 GLI2 GLI3 SHH
27 proximal/distal pattern formation GO:0009954 9.85 CTNNB1 GLI1 GLI2 GLI3
28 intermediate filament organization GO:0045109 9.84 KRT17 KRT20 SHH
29 positive regulation of protein import into nucleus GO:0042307 9.84 GLI3 SHH SMO
30 renal system development GO:0072001 9.84 CTNNB1 PTCH1 SHH SMO
31 epithelial tube branching involved in lung morphogenesis GO:0060441 9.83 CTNNB1 HHIP SHH
32 somite development GO:0061053 9.83 PTCH1 SHH SMO
33 anatomical structure development GO:0048856 9.83 GLI2 GLI3 SHH
34 spinal cord motor neuron differentiation GO:0021522 9.83 GLI2 GLI3 PTCH1 SHH
35 odontogenesis of dentin-containing tooth GO:0042475 9.83 CTNNB1 GLI2 GLI3 SHH SMO
36 cell fate specification GO:0001708 9.82 CTNNB1 SHH SMO
37 positive regulation of neuroblast proliferation GO:0002052 9.81 CTNNB1 GLI3 SHH SMO
38 pattern specification process GO:0007389 9.8 GLI2 GLI3 PTCH1 SHH SMO
39 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.79 GLI2 GLI3 PTCH1
40 digestive tract morphogenesis GO:0048546 9.77 GLI1 SHH
41 ectoderm development GO:0007398 9.77 CTNNB1 SHH
42 mammary gland epithelial cell differentiation GO:0060644 9.77 PTCH1 SMO
43 regulation of osteoblast differentiation GO:0045667 9.77 CTNNB1 GLI1
44 thalamus development GO:0021794 9.77 SHH SMO
45 cellular response to cholesterol GO:0071397 9.77 PTCH1 SMO
46 layer formation in cerebral cortex GO:0021819 9.77 CTNNB1 GLI3
47 keratinocyte proliferation GO:0043616 9.76 PTCH1 WNT16
48 negative thymic T cell selection GO:0045060 9.76 GLI3 SHH
49 replicative senescence GO:0090399 9.76 TP53 WNT16
50 positive regulation of T cell differentiation in thymus GO:0033089 9.76 GLI2 SHH

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.77 CTNNB1 GLI1 GLI2 GLI3 TP53
2 transcription regulatory region DNA binding GO:0044212 9.73 CTNNB1 GLI1 GLI2 TP53
3 structural constituent of cytoskeleton GO:0005200 9.46 KRT15 KRT17 KRT19 KRT20
4 hedgehog receptor activity GO:0008158 9.32 PTCH1 PTCH2
5 smoothened binding GO:0005119 9.26 PTCH1 PTCH2
6 patched binding GO:0005113 9.13 PTCH1 SHH SMO
7 hedgehog family protein binding GO:0097108 8.8 HHIP PTCH1 PTCH2
8 protein binding GO:0005515 10.33 CTNNB1 GLI1 GLI2 GLI3 GSTM3 HHIP

Sources for Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....